UY39221A - Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos - Google Patents

Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos

Info

Publication number
UY39221A
UY39221A UY0001039221A UY39221A UY39221A UY 39221 A UY39221 A UY 39221A UY 0001039221 A UY0001039221 A UY 0001039221A UY 39221 A UY39221 A UY 39221A UY 39221 A UY39221 A UY 39221A
Authority
UY
Uruguay
Prior art keywords
cov
methods
same
sars
selection
Prior art date
Application number
UY0001039221A
Other languages
English (en)
Inventor
Mark Esser
James Steinhardt
MCTAMNEY II Patrick
LOO Yueh-Ming
M Varkey Reena
Qun Du
Saravanan RAJAN
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of UY39221A publication Critical patent/UY39221A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002Coronaviridae
    • C07K16/1003Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/165Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente a la proteína espicular del SARS-CoV-2 y métodos para elaborar y seleccionar los mismos. Los anticuerpos pueden usarse, por ejemplo, en la profilaxis, profilaxis posterior a la exposición o tratamiento de la infección por SARS-CoV-2. Los anticuerpos también se pueden usar para detectar la infección por SARS-CoV-2 en un sujeto.
UY0001039221A 2020-05-17 2021-05-18 Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos UY39221A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063026121P 2020-05-17 2020-05-17

Publications (1)

Publication Number Publication Date
UY39221A true UY39221A (es) 2021-12-31

Family

ID=76098926

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039221A UY39221A (es) 2020-05-17 2021-05-18 Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos

Country Status (19)

Country Link
US (2) US20210355196A1 (es)
EP (1) EP4153312A1 (es)
JP (1) JP2023528235A (es)
KR (1) KR20230010749A (es)
CN (1) CN115697491A (es)
AR (1) AR122111A1 (es)
AU (1) AU2021275361A1 (es)
BR (1) BR112022023088A2 (es)
CA (1) CA3182150A1 (es)
CL (1) CL2022003177A1 (es)
CO (1) CO2022017690A2 (es)
CR (1) CR20220646A (es)
EC (1) ECSP22094536A (es)
IL (1) IL297977A (es)
MX (1) MX2022014422A (es)
PE (1) PE20231376A1 (es)
TW (1) TW202208423A (es)
UY (1) UY39221A (es)
WO (1) WO2021233834A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020340881A1 (en) 2020-04-02 2021-10-21 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
CN116057069A (zh) 2020-06-03 2023-05-02 瑞泽恩制药公司 用抗SARS-CoV-2刺突糖蛋白抗体治疗或预防SARS-CoV-2感染和COVID-19的方法
BR112023002234A2 (pt) * 2020-08-10 2023-03-07 Astrazeneca Uk Ltd Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CA3225575A1 (en) * 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023141176A2 (en) * 2022-01-19 2023-07-27 Icahn School Of Medicine At Mount Sinai Neutralizing antibodies and antigen-binding fragments thereof against omicron and other coronavirus variants, and methods of making and using the same
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
CN115286712B (zh) * 2022-03-18 2024-09-27 北京百普赛斯医学检验实验室有限公司 新型冠状病毒Delta突变株特异性抗体及其应用
CN116041494B (zh) * 2022-12-12 2024-08-20 首都医科大学 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
WO2002000879A2 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk METHOD FOR PURIFYING ANTIBODIES
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ, スーパーヒト化抗体
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2478297C (en) 2002-03-19 2013-05-14 Plant Research International B.V. Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
KR101292000B1 (ko) 2003-01-22 2013-08-01 로슈 글리카트 아게 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이증가된 항체를 생성하기 위한 이의 용도
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
US8716557B2 (en) 2006-01-17 2014-05-06 Synthon Biopharmaceuticals B.V. Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
BRPI1007005A2 (pt) 2009-01-29 2016-03-22 Medimmune Llc anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
MX2022011142A (es) * 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
WO2021203053A1 (en) * 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses

Also Published As

Publication number Publication date
TW202208423A (zh) 2022-03-01
AU2021275361A1 (en) 2023-01-19
CL2022003177A1 (es) 2023-07-28
IL297977A (en) 2023-01-01
EP4153312A1 (en) 2023-03-29
CN115697491A (zh) 2023-02-03
WO2021233834A1 (en) 2021-11-25
CR20220646A (es) 2023-10-23
US20210355196A1 (en) 2021-11-18
ECSP22094536A (es) 2023-01-31
CO2022017690A2 (es) 2022-12-20
AR122111A1 (es) 2022-08-17
BR112022023088A2 (pt) 2022-12-20
CA3182150A1 (en) 2021-11-25
JP2023528235A (ja) 2023-07-04
PE20231376A1 (es) 2023-09-07
US20240182548A1 (en) 2024-06-06
MX2022014422A (es) 2022-12-07
KR20230010749A (ko) 2023-01-19

Similar Documents

Publication Publication Date Title
ECSP22094536A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CO2020016559A2 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
ECSP21022299A (es) Anticuerpos de anti-cd33 y métodos para usarlos
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
CL2020003168A1 (es) Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis
CO2022010204A2 (es) Anticuerpos contra la integrina alfa 11 beta 1
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CL2021002169A1 (es) Métodos para obtener células de músculo liso inducidas
EA201991716A1 (ru) АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ГЕНТИНГТОНА
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma
CL2018001873A1 (es) Anticuerpos igy para la prevención de infestación e infección de liendres marinas
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos
EA202190361A1 (ru) Лечение рецидивирующей фолликулярной лимфомы
CL2022002938A1 (es) Formulación sistémica de un derivado de la piridinona para la enfermedad celíaca
EA202191388A1 (ru) Лечение головной боли при избыточном применении лекарственных препаратов антителами к cgrp или cgrp-r
AR104931A1 (es) Métodos para tratar cáncer usando anticuerpos anti-ox40 y antagonistas de unión al eje pd-1
AR116106A1 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
EA201991135A1 (ru) Комбинированная терапия ингибиторами аргиназы